Functional ConstipationPhase 2NCT02314936
Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
A Phase 2 study testing Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose in people with Functional Constipation, run by KGK Science Inc. at 1 site in Canada.
Trial summary
This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g of Polydextrose daily, one quarter will… Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Functional Constipation
- What is being tested?
- Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 192 participants
- Where
- 1 siteCanada
- Study dates
- Apr 2015to May 2016
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 18 and 70 years.
- Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight).
- If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).
- OR
- Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System), Intrauterine devices, Double barrier method, Vasectomy of partner (shown successful as per appropriate follow-up), Tubal ligation, and Non-heterosexual lifestyle (same sex partner).
Show all 15Show fewer
- Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):
- Must meet 2 or more of the following criteria:
- Straining during at least 25% of defecations, Lumpy or hard stools in at least 25% of defecations, Sensation of incomplete evacuation for at least 25% of defecations, Sensation of anorectal obstruction/blockage for at least 25% of defecations, Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
- Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for irritable bowel syndrome
- Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects.
- Consent to the study and willing to comply with study product and methods.
- Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
Who cannot join
- Major gastrointestinal complication (e.g. Crohn's disease, colitis, celiac disease)
- Prior abdominal surgery that in the opinion of the investigator may present a risk for the subject or confound study results.
- Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness).
- Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening and throughout the trial other than the provided study products.
- Laxative use within 48 hours of screening (rescue medication allowed for intolerable symptoms during study).
- Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-HT#-antagonists, antacids with magnesium, calcium or aluminum, antidiarrheal medication, anticholinergic agents, calcium supplements, calcium channel blockers, tricyclic antidepressants or NSAIDs), within 1 month before screening.
Show all 16Show fewer
- Anticipated major dietary or exercise changes during the study.
- Systemic steroid use, within 1 month before screening.
- Eating disorder.
- Contraindication to dairy products (e.g., intolerance to lactose or any substance in the study product).
- History of alcohol, drug, or medication abuse.
- Pregnant or lactating female, or pregnancy planned during study period.
- Participation in another study with any investigational product within 60 days of screening.
- Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study.
- Subject under administrative or legal supervision.
- Subject who would receive more than 4500 Euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial
This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g of Polydextrose daily, one quarter will receive 4 g of Polydextrose daily and one quarter will receive a placebo daily.
- Conditions
- Functional Constipation
- Being tested
- Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose, Litesse powder containing 4 g polydextrose, Placebo
- Keywords
- Constipation, Polydextrose, Dietary Fiber, PAC-QoL, Colonic Transit Time, PAC-SYM
- Medical subject headings
- Constipation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Litesse powder containing 12 g polydextroseDietary supplement
Also called Litesse powder
12 g polydextrose
Litesse powder containing 8 g polydextroseDietary supplement
Also called Litesse powder
8 g polydextrose, 4 g maltodextrin
Litesse powder containing 4 g polydextroseDietary supplement
Also called Litesse powder
4 g polydextrose, 8 g maltodextrin
PlaceboDietary supplement
12 g Maltodextrin
| Study group | Role | What they receive |
|---|---|---|
| Litesse powder containing 12 g polydextrose | Experimental | 12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks Receives: Dietary Supplement: Litesse powder containing 12 g polydextrose |
| Litesse powder containing 8 g polydextrose | Experimental | 8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks Receives: Dietary Supplement: Litesse powder containing 8 g polydextrose |
| Litesse powder containing 4 g polydextrose | Experimental | 4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks Receives: Dietary Supplement: Litesse powder containing 4 g polydextrose |
| Placebo | Placebo comparator | Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Colonic Transit Time From Baseline to Day 15
Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.
Measured: Baseline and Day 15
Secondary outcomes (11)
Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15
Assessed using the PAC-SYM questionnaire (overall score, abdominal symptoms score, rectal symptoms score, and stool symptoms score).
The PAC-SYM was developed as a brief, easily administered tool to assess symptom frequency and severity of chronic constipation. The authors used a definition for constipation was based on the Rome II criteria. This 12-item self-report measure is divided into the 3 symptom subscales of: abdominal, rectal and stool subscales.
All items (sub-scores and the total score) are scored on a five-point Likert scale ranging from 0 (absence of symptom) to 4 (very severe) where lower scores are better. Scores for the total number of non-missing items within the subscale or total score are summed and divided by the total number of non-missing items for that subscale or total score.
Measured: Baseline and Day 15
Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15
Assessed using the PAC-QoL questionnaire (Overall Score, Worries and Concerns Score, Physical Discomfort Score, Psychosocial Discomfort Score, and Satisfaction Score)
The Patient Assessment of Constipation (PAC) was developed to address the need for a disease-specific patient-reported outcomes measure. It includes components from complementary symptom and quality of life questionnaires.
The PAC-QOL contains 28 items grouped into 4 subscales covering: worries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort (8 items), and satisfaction (5 items).
A 5-point Likert response scale, ranging from 0 (not at all / none of the time) to 4 (extremely / all of the time), where lower scores are better. Scores are computed as the average non-missing item response within the subscale where each score is given equal weight; the global score is calculated as the mean of the 28-items.
Measured: Baseline and Day 15
Change in Bowel Function Index From Baseline to Day 15
Assessed using the Bowel Function Index questionnaire (total score, ease of defecation, feeling of incomplete bowel evacuation, and personal judgement of constipation).
Each of the three questions used a numerical analog scale (0 = easy/no difficulty/not at all, 100 = very strong/very difficult) for grading purposes. The three questions were calculated as single scores as well as by a total score defined as the average of the three questions.
Measured: Baseline and Day 15
Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15
Assessed using single question dichotomous tool.
Adequate relief quantified the difference in the number of participants experiencing relief from constipation between participants supplemented with Litesse and those supplemented with a placebo at baseline and day 14. The units of analysis for the relief questionnaire were the number of participants who reported relief from constipation.
Measured: Baseline and Day 15
Change in Stool Frequency From Baseline to Day 15
Participants will record the number of defecations per day in a daily diary
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Change in Stool Consistency From Baseline to Day 15
Stool consistency will be rated each day in a diary by using the Bristol Stool Scale Form.
Bristol Stool Scale:
The BSS is a categorical scale ranging from 1 to 7 that interprets the consistency of a single bowel movement; a single score is recorded and used for analysis. Lower scores are associated with hard and lumpy consistencies while higher scores are associated with soft or liquid consistencies. Generally, an optimal BSS scores ranges from 3 to 5.
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Degree of Straining During Defecation From Baseline to Day 15
Degree of straining for each bowel movement will be recorded in a daily diary using a 5-point scale.
The degree of straining is a rating scale ranging from 1 (not at al) to 5 (an extreme amount) that interprets the degree to which an individual must strain during a unique defecation; a single core is recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of straining (1-5) where a lower score represented less straining.
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15
Sensation of complete bowel emptying for each bowel movement will be recorded in a daily diary on a dichotomous "yes" or "no" scale.
The change in the sensation was defined as the change from baseline to week 2 in the percentage of complete bowel movements (CBMs) between participants supplemented with Litesse and those supplemented with a placebo. It assessed whether the participant felt as though their bowel movement was complete. The units of analysis for the sensation of complete bowel emptying was the weekly percentage of complete bowel movements, for each participant at run-in (week -1), week 1 and week 2.
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Severity of Abdominal Discomfort From Baseline to Day 15
Severity of abdominal discomfort will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal discomfort was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of discomfort where a lower score represented less straining.
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Bloating Severity From Baseline to Day 15
Severity of bloating will be recorded each day in a daily diary on a 5-point scale.
The severity of abdominal bloating was calculated from a rating scale ranging from 1 (not at all) to 5 very severe); a single score was recorded and used for analysis. Scores were calculated as the weekly average of the daily degree of bloating where a lower score represented less straining.
Measured: 14 day run-in and Week 2 of the 14-day supplementation period
Overall Product Satisfaction
Participants will be asked to rate their overall satisfaction with the study product's ability to relieve their constipation symptoms on a 5-point ordinal scale.
The overall product satisfaction questionnaire consists of a single question that provides insight regarding the participants satisfaction on the product's ability to relieve constipation symptoms. The score that the participant indicates is considered the total score and no sub-scores are calculated. It is a rating scale that ranges from 1 (not at all satisfied) to 5 (very satisfied) where a higher score at the end-of-study indicates an improvement.
Measured: Assessed at Day 15 (end of study)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2014 (estimated)
- Study startApr 2015
- Primary completionApr 2016
- Study completionMay 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Functional ConstipationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 192 participants (actual)
Sponsor and investigators
- Lead sponsor
- KGK Science Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- DuPont Nutrition and Health
- Responsible party
- Sponsor
- Investigators
- Tetyana Pelipyagina, MD, Principal investigator, KGK Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02314936
- Sponsor's protocol ID
- 01-2014
- Status last verified
- Apr 2018
- First submitted
- 8 Dec 2014
- Last updated
- 9 Nov 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial
- ClinicalTrials.gov ID
- NCT02314936
- Acronym / sponsor ID
- 01-2014
- Conditions
- Functional Constipation
- Keywords
- Constipation, Polydextrose, Dietary Fiber, PAC-QoL, Colonic Transit Time, PAC-SYM
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 192 participants (actual)
- Lead sponsor
- KGK Science Inc.Industry (pharma, biotech, devices)
- Collaborators
- DuPont Nutrition and Health
- Study start
- Apr 2015
- Primary completion
- Apr 2016 (actual)
- Study completion
- May 2016 (actual)
- First posted
- 11 Dec 2014 (estimated)
- Results
- Posted 9 Nov 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate the effectiveness of Polydextrose, a dietary fiber, at decreasing Colonic Transit Time and the gastrointestinal symptoms of Functional Constipation. One quarter of the subjects will receive 12 g of Polydextrose daily, one quarter will receive 8 g of Polydextrose daily, one quarter will receive 4 g of Polydextrose daily and one quarter will receive a placebo daily.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Litesse powder containing 12 g polydextrose | Experimental | Dietary Supplement: Litesse powder containing 12 g polydextrose12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks |
| Litesse powder containing 8 g polydextrose | Experimental | Dietary Supplement: Litesse powder containing 8 g polydextrose8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks |
| Litesse powder containing 4 g polydextrose | Experimental | Dietary Supplement: Litesse powder containing 4 g polydextrose4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboMaltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Age between 18 and 70 years.
- Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight).
- If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).
- OR
- Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
Key exclusion criteria (16 listed)
- Major gastrointestinal complication (e.g. Crohn's disease, colitis, celiac disease)
- Prior abdominal surgery that in the opinion of the investigator may present a risk for the subject or confound study results.
- Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may confound the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness).
- Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening and throughout the trial other than the provided study products.
- Laxative use within 48 hours of screening (rescue medication allowed for intolerable symptoms during study).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Litesse powder containing 12 g polydextroseAlso: Litesse powder12 g polydextrose | Dietary supplement | Litesse powder containing 12 g polydextrose |
| Litesse powder containing 8 g polydextroseAlso: Litesse powder8 g polydextrose, 4 g maltodextrin | Dietary supplement | Litesse powder containing 8 g polydextrose |
| Litesse powder containing 4 g polydextroseAlso: Litesse powder4 g polydextrose, 8 g maltodextrin | Dietary supplement | Litesse powder containing 4 g polydextrose |
| Placebo12 g Maltodextrin | Dietary supplement | Placebo |
Primary outcome
Change in Colonic Transit Time From Baseline to Day 15
Time frame: Baseline and Day 15
Assessed using abdominal x-ray. Subjects will take 24 radiopaque markers for 6 consecutive days (144 radiopaque markers in total) immediately preceding the x-ray dates.
11 secondary outcomes
Change in Participant Assessment of Constipation Symptoms (PAC-SYM) From Baseline to Day 15
Time frame: Baseline and Day 15
Change in Participant Assessment of Constipation Quality of Life (PAC-QoL) From Baseline to Day 15
Time frame: Baseline and Day 15
Change in Bowel Function Index From Baseline to Day 15
Time frame: Baseline and Day 15
Change in Adequate Relief of Constipation Symptoms From Baseline to Day 15
Time frame: Baseline and Day 15
Change in Stool Frequency From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Change in Stool Consistency From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Degree of Straining During Defecation From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Sensation of Complete Bowel Emptying From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Severity of Abdominal Discomfort From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Change in the Bloating Severity From Baseline to Day 15
Time frame: 14 day run-in and Week 2 of the 14-day supplementation period
Overall Product Satisfaction
Time frame: Assessed at Day 15 (end of study)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Functional Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
Active, not recruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Functional Constipation (FC)
Not yet recruitingPhase 3
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
Bloating, Rifaximin
Recruiting
Effects of Connective Tissue Massage Plus Biofeedback for Dyssynergic Defecation
Dyssynergic Defecation
RecruitingObservational study
Relationship Between Interoception and Postural Control in Constipation-Predominant Irritable Bowel Syndrome
Constipation, Irritable Bowel Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tetyana Pelipyagina, MD principal investigator
KGK Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Litesse powder containing 12 g polydextrose, Litesse powder containing 8 g polydextrose and Litesse powder containing 4 g polydextrose in people with Functional Constipation, run by KGK Science Inc. at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Colonic Transit Time From Baseline to Day 15 (time frame: Baseline and Day 15). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2018.